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Although fosfomycin used to be primarily designated for
urinary tract infection treatments, the lack of available anti-
biotics to treat carbapenemase producers has given fosfomycin
an important adjuvant role, mainly in more severe infection
cases. Despite that, according to results reported by
Karageorgopoulos et al5 as well as this present study where
the emergence of fosfomycin resistance was reported just
shortly after its introduction in clinical practices (mid-2014),
fosfomycin resistance has become a concern because the
endemic level reached by the KPC-2-Kp is due to its great
ability to adapt and survive,8,9 characteristics that came as an
advantage mainly through antimicrobial selective pressure,
strongly driven by the previous use, showing the need to
establish a rigorous protocol for antimicrobial consumption.
The limitation of this study is due to the unknown genetic
background information on which mechanism is involved to
confer resistance to fosfomycin. So, further studies should be
performed in order to detect possible genetic targets, such as
fosA3 gene, that encode for a speciﬁc enzyme and which have
recently resulted in a high resistance level to fosfomycin among
European KPC-producers.10
In conclusion, this study reports a signiﬁcant emergence
of fosfomycin resistance among KPC-2-Kp isolates in a
relatively short period after the introduction of this antibiotic
as an effective agent to treat KPC infections. Strict
control practices are urgently required in order to avoid the
resistance rate increase, regardless of the mechanism by which
it occurs.
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Prevalence of Asymptomatic Bacteriuria in
Hospitalized Patients
To the Editor—The prevalence of asymptomatic bacteriuria
(ASB) varies widely based on the studied population.
Currently, the prevalence of ASB in patients hospitalized in
acute care institutions is unknown. Awareness of the pre-
valence of ASB in this setting would be useful in both medical
decision making as well as public reporting of hospital-
acquired urinary tract infections. In this prevalence study, 200
randomly selected patients admitted in April/May 2013 to a
tertiary care academic center had urine samples collected for
culture within 24 hours of being admitted. Data from the
medical records were collected during these hospitalizations
up to 30 days post-enrollment. The objective was to determine
the prevalence of ASB. Of the 200 patients, 17 were found to
have ASB for a prevalence of 8.5%.
Because infections acquired during a hospital stay are not
always reimbursed by insurers, knowing what conditions were
present on admission can be relevant from the hospital’s
perspective. ASB, usually deﬁned as 1 (in men) or 2 separate
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(in women) urine samples with microbial growth above a
certain threshold in the absence of typical urinary tract
symptoms, is such a condition. While the prevalence of ASB in
patients hospitalized in acute care institutions is currently
unknown, it has been determined in other populations and
ranges from 1% to 5% in healthy premenopausal women to
100% in long-term catheterized patients.1 ASB should not
routinely be screened for; however, if it is ﬁrst detected during
the hospital stay after a catheter is placed or during a fever, it can
easily be misinterpreted as healthcare-associated.2 ASB is not a
treatment indication (with few exceptions) but inappropriate
antibiotic administration for ASB is common and associated with
higher occurrence of antibiotic-resistant bacteria generating a
major opportunity for antimicrobial stewardship.3,4 Our objec-
tive was to determine the prevalence of ASB among patients
admitted to an academic medical center.
methods
We conducted a prevalence study from April 1 to May 31,
2013, and included 200 adult patients who were admitted to
Barnes-Jewish Hospital, a 1,250-bed university-afﬁliated
tertiary care center in St. Louis, Missouri, for a variety of rea-
sons with the exception of a UTI diagnosis (or compatible
symptoms). To apply inclusion and exclusion criteria, a
convenience sample of 5–10 newly admitted patients were
interviewed within 24 hours and asked for any urinary tract
symptoms. Other exclusion criteria were fever ≥38°C of
unknown etiology (because UTI could be part of the
differential diagnosis) and patients unable to communicate
their symptoms. After obtaining informed consent, a mid-
stream clean-catch urine sample was collected in the same
24-hour time window and was evaluated for urinalysis using a
dipstick test and routine culture. A positive urine culture
was deﬁned as a single urine sample with microbial growth
of >105 colony-forming units of a single organism.2 Data from
the medical record were collected during the patient’s
hospitalization, ending 30 days post-enrollment (if the patient
was still admitted at that point). We considered a sequence of 200
enrolled patients in the order of their admission to the hospital
(without prior sample size calculation). The results were not
shared with the treating physicians. The Washington University
Institutional Review Board approved the study.
results
Of the 200 included patients, 110 were women (55%). The
mean age was 47.8 years (±16.5). Most patients were white
(112; 56%) or African-American (83; 41.5%). The admitting
service was general medicine in 139 patients (69.5%) and
neurology in 19 patients (9.5%), with comparatively fewer
patients admitted to surgical services. In addition, 41 patients
(20.5%) carried a diagnosis of diabetes mellitus. None of the
patients had a urinary catheter in place on the day of
admission.
Of the 200 patients, 17 (8.5%) were found to have ASB; all 17
were women. Another 102 (51%) patients had positive urine
cultures but with insigniﬁcant growth according to the deﬁnition
set forth above. The retrieved organisms are shown in Table 1.
Comparing patients with ASB versus no ASB, there were no
differences in age or race. Both the proportion of patients
admitted to the ICU during their stay (1 patient of 17 patients
[5.9%] with ASB vs 8 patients of 183 patients [4.4%] without
ASB; P= .7) and the overall length of hospital stay (3 days [range,
2–10] vs 3 days [range, 2–34]; P= .7) were similar. Only 1 of the
200 patients was diagnosed with a UTI over the course of hos-
pitalization, and 1 fatality occurred among the cohort; both of
these occurred in the non-ASB group. During their hospital
stays, 2 patients had a urinary catheter, and 14 of the 200 were
receiving antimicrobials on admission (all in the non-ASB
group). No ASB patient received therapy, as the culture results
were not disclosed to treating physicians.
discussion
We found the prevalence of asymptomatic bacteriuria to be
8.5% in a general hospital population on the day of admission,
with all affected patients being women and Enterobacteriaceae
being the most common pathogen group. This rate is similar
to data from other populations; however, to our knowledge,
ASB prevalence has never been determined for acute care
hospital admissions.5–7 The signiﬁcance of the 51% samples
with growth in urine cultures below the threshold is unclear;
none of them developed a symptomatic UTI while being
admitted. When obtaining urine cultures in patients admitted
to an acute care hospital, providers should be aware that
approximately 1 in 10 may arrive with ASB.
Our study had several limitations. It was a single-center
study, and enrolled patients were middle-aged adults admitted
mostly to lower acuity wards under general medicine or neu-
rology services. Thus, the ﬁndings are difﬁcult to generalize.
Regardless, when working up a possible infection over the
table 1. Urine Culture Results in 200 Patients Screened for
Asymptomatic Bacteriuria Upon Admission
Urine Culture Results No. (%)
Total samples 200 (100)
Clinically insigniﬁcant growth (<105 CFU) 102 (51.0)
Asymptomatic bacteriuria 17 (8.5)
Total organisms detected 18 (100)
Escherichia coli 4 (22)
Klebsiella pneumoniae 4 (22)
Streptococcus Group B 3 (17)
Coagulase-negative Staphylococcus 2 (11)
Enterococcus spp. 2 (11)
Lactobacillus spp. 1 (6)
Providencia rettgeri 1 (6)
Other Gram-negative bacilli 1 (6)
NOTE. CFU, colony-forming units.
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hospital course that would qualify as hospital-acquired, the
possibility of ASB that was present on admission should be
given consideration.
Given that a substantial number of patients receive unne-
cessary antibiotics while hospitalized, these results serve as a
reminder that the clinical picture must not be forgotten when
interpreting laboratory ﬁndings. This is particularly relevant
for positive urine cultures, a common justiﬁcation for starting
antibiotics irrespective of symptoms.8–10 Raising the awareness
of ASB and its potential misinterpretation as nosocomial
bacteriuria can lead to lower antibiotic consumption and thus
decrease the development of antimicrobial resistance.
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